Antifungal susceptibility profiles and drug resistance mechanisms of clinical Candida duobushaemulonii isolates from China
Journal
Frontiers in microbiology
Journal Volume
13
Date Issued
2022
Author(s)
Chen, Xin-Fei
Zhang, Han
Jia, Xin-Miao
Cao, Jin
Li, Li
Hu, Xin-Lan
Li, Ning
Xiao, Yu-Ling
Xia, Fei
Ye, Li-Yan
Hu, Qing-Feng
Wu, Xiao-Li
Ning, Li-Ping
Fan, Xin
Yu, Shu-Ying
Huang, Jing-Jing
Xie, Xiu-Li
Yang, Wen-Hang
Li, Ying-Xing
Zhang, Ge
Zhang, Jing-Jia
Duan, Si-Meng
Kang, Wei
Wang, Tong
Li, Jin
Xiao, Meng
Hou, Xin
Xu, Ying-Chun
Abstract
Candida duobushaemulonii, type II Candida haemulonii complex, is closely related to Candida auris and capable of causing invasive and non-invasive infections in humans. Eleven strains of C. duobushaemulonii were collected from China Hospital Invasive Fungal Surveillance Net (CHIF-NET) and identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF), VITEK 2 Yeast Identification Card (YST), and internal transcribed spacer (ITS) sequencing. Whole genome sequencing of C. duobushaemulonii was done to determine their genotypes. Furthermore, C. duobushaemulonii strains were tested by Sensititre YeastOne™ and Clinical and Laboratory Institute (CLSI) broth microdilution panel for antifungal susceptibility. Three C. duobushaemulonii could not be identified by VITEK 2. All 11 isolates had high minimum inhibitory concentrations (MICs) to amphotericin B more than 2 μg/ml. One isolate showed a high MIC value of ≥64 μg/ml to 5-flucytosine. All isolates were wild type (WT) for triazoles and echinocandins. FUR1 variation may result in C. duobushaemulonii with high MIC to 5-flucytosine. Candida duobushaemulonii mainly infects patients with weakened immunity, and the amphotericin B resistance of these isolates might represent a challenge to clinical treatment.
Subjects
Candida duobushaemulonii; FUR1; antifungal susceptibility; drug resistance mechanisms; whole genome sequence
SDGs
Publisher
FRONTIERS MEDIA SA
Type
journal article